Glyscend taps CEO to lead oral obesity, type 2 diabetes candidate; Ex-Travecta chief bounces back after company shutdown

2023-09-08

临床2期高管变更

As a new wave of type 2 diabetes and obesity drugs takes the industry by storm, Glyscend Therapeutics has tapped a new CEO to lead the charge for its candidate designed to mimic metabolic surgery. Sapan Shah is taking the driver’s seat at Glyscend as founding CEO Ashish Nimgaonkar shifts to other roles as chief medical officer and head of R&D, the company announced on Tuesday. The news comes just a few months after Glyscend unveiled topline data from a Phase IIa suggesting its lead candidate, GLY-200 , helped type 2 diabetes patients achieve significant reductions in blood glucose and a decrease in body weight. The company hopes the oral drug will have the same effects as metabolic surgery without the cost and complications from the invasive procedure.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构